How the Food and Drug Administration will approach measuring the benefits of these drugs for the purpose of approving them is uncertain. FDA draft guidelines published in January say loss of lean ...

Its drug helped improve motor function for patients with spinal muscular atrophy in a late-stage study. The mid-stage study plans to enroll 100 patients and evaluate changes in total lean mass ...

“The body of evidence for the GLP-1 drug class shows that up to 40% of total weight loss in GLP-1 patients is lean body mass including skeletal muscle mass, 1 ” said Mitchell Glass, M.D ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...